期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
化瘀消癥颗粒口服联合止痛消癥颗粒保留灌肠、GnRH-a治疗复发性子宫内膜异位症临床观察 被引量:1
1
作者 姚奏英 叶玲红 +3 位作者 陈青微 武蓉贞 卢锦 黄悦来 《药物流行病学杂志》 CAS 2023年第2期178-187,共10页
目的观察促性腺激素释放激素激动药(GnRH-a)治疗基础上,加用化瘀消癥颗粒口服联合止痛消癥颗粒保留灌肠治疗复发性子宫内膜异位症的临床疗效。方法复发性子宫内膜异位症患者168例随机分为4组(A、B、C、D组)各42例。A组给予醋酸亮丙瑞林... 目的观察促性腺激素释放激素激动药(GnRH-a)治疗基础上,加用化瘀消癥颗粒口服联合止痛消癥颗粒保留灌肠治疗复发性子宫内膜异位症的临床疗效。方法复发性子宫内膜异位症患者168例随机分为4组(A、B、C、D组)各42例。A组给予醋酸亮丙瑞林微球治疗,B组在A组基础上加用化瘀消癥颗粒口服治疗,C组在A组基础上加用止痛消癥颗粒保留灌肠治疗,D组在A组基础上同时加用化瘀消癥颗粒口服联合止痛消癥颗粒保留灌肠治疗。比较4组患者治疗前后主要临床症状、生存质量、血清糖抗原125(CA125)和血管内皮生长因子(VEGF)水平变化,观察4组的临床疗效和药品不良反应。结果治疗后4组的临床症状评分、生存质量评分、血清CA125和VEGF水平均较治疗前下降(P<0.05),且B、C、D组均明显低于A组,D组明显低于B、C组(P<0.05),B、C组间差异无统计学意义(P>0.05)。D组总有效率高于A组(P<0.0083),但与B、C组总有效率比较无统计学差异(P>0.0083);4组药品不良反应发生率的差异无统计学意义(P>0.05)。结论复发性子宫内膜异位症患者在GnRH-a醋酸亮丙瑞林微球治疗基础上,加用瘀消癥颗粒口服联合止痛消癥颗粒保留灌肠,可缓解临床症状、改善患者生存质量,降低血清CA125和VEGF水平,效果良好。 展开更多
关键词 复发性子宫内膜异位症 化瘀消癥颗粒 止痛消癥颗粒 保留灌肠 醋酸亮丙瑞林微球 临床疗效
下载PDF
Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy
2
作者 Yong Chai Rong-Qiang Liu +4 位作者 Jing-Lin Yi ling-hong ye Jing Zou Nan Jiang Yi Shao 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2016年第10期1444-1450,共7页
AIM:To compare the effectiveness of combined fenofibrate and spironolactone with fenofibrate alone for treatment of central serous chorioretinopathy(CSCR).METHODS: Totally 60 patients(60 eyes) with a history of ... AIM:To compare the effectiveness of combined fenofibrate and spironolactone with fenofibrate alone for treatment of central serous chorioretinopathy(CSCR).METHODS: Totally 60 patients(60 eyes) with a history of acute CSCR were randomed into two groups: group A with combination of fenofibrate(200 mg) and spironolactone(100 mg),and group B with only fenofibrate(200 mg).They were taken half an hour before meals and once per day for 8wk.The changes of the visual acuity,subjective symptom,ocular surface disease index(OSDI),the tear film and optical coherence tomography were observed at 2,4,6,and 8wk before and after treatment.RESULTS: The best corrected visual acuity(BCVA,log MAR) was improved to 0.22 and 0.27 after treatment from baseline of 0.35 and 0.36 in groups A and B(P 〈0.05),respectively.After 8wk treatment,the central subfield thickness(CST),and subretinal fluid volumn(SFV) decreased significantly to 49.5% and 78.8% in group A,37.0% and 57.2% in group B.There were significant differences of CST and SFV in both groups(all P 〈0.05).CONCLUSION:Fenofibratecombinedwithspironolactone may have more clinical efficacy in the treatment of CSCR than fenofibrate only. 展开更多
关键词 FENOFIBRATE SPIRONOLACTONE central serous chorioretinopathy VISION optical coherence tomography
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部